Hollywood actor Angelina Jolie's public disclosure in 2013 regarding her surgery for breast cancer led to a spike in genetic tests for a gene known to increase the deadly disease, a study has found.
Jolie lost her mother to ovarian and breast cancer and grandmother and aunt to breast cancer. In an op-ed piece in The New York Times -- a major US daily -- Jolie announced that she had undergone surgery in order to reduce her chances of getting the disease.
"My doctors estimated that I had an 87 per cent risk of breast cancer and a 50 per cent risk of ovarian cancer...I made a decision to have a preventive double mastectomy," wrote Jolie, in the article on May 14, 2013.
According to the study, led by researchers from Harvard Medical School in Boston, US, the rates of genetic testing for breast cancer increased by 64 per cent in the two weeks following Jolie's testimonial.
However, the rates of mastectomy did not increase among women who underwent BRCA gene testing. This suggests those who received the genetic test had a low risk of carrying the mutation in the first place, the researchers said.
The results illustrate that celebrity endorsements can fuel the use of health care services but may not effectively target the populations in greatest need of such services.
"Our findings underscore celebrity endorsements as a powerful influence on health-related behaviours, but they also show that such endorsements do not necessarily target those most at risk for developing a disease," said lead investigator Sunita Desai from Harvard Medical School in Boston, US.
When people request a test or an intervention based on a celebrity endorsement, it is critical that physicians provide careful assessment of a patient's medical and family history with clear explanations about the pros and cons of choosing to have the test versus foregoing testing in the context of the individual's specific circumstances, the researchers suggested, in the study published in The BMJ in December, 2016.
--IANS
rt/vgu/bg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
